Regeneron Pharmaceuticals Inc Reports 53% Increase in Earnings Per Share

Regeneron Pharmaceuticals Inc has announced its financial results for the second quarter, reporting a 53% increase in earnings per share compared to the same period in the previous year.

The company’s strong earnings and sales performance have contributed to a rise in its stock price, with investors reacting favorably to the results.

Key Financial Highlights

• Earnings per share increased by 53% in the second quarter
• The company’s stock price has risen in response to the strong earnings and sales performance

Product Performance

• The Dupixent product is expected to reach $17 billion in annual sales
• 10 new registrational trials have been initiated for Dupixent

Regulatory Update

• The FDA has rejected Regeneron’s lymphoma therapy odronextamab for the second time, citing concerns over a third-party manufacturing site

Stock Performance

• Despite the setback, the company’s stock continues to trade up, driven by its robust Q2 growth and strong sales of its Eylea HD product